Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Mouse MIP1 alpha was tested for its ability to neutralize the bioactivity of recombinant, mouse MIP1 alpha in a cell proliferation assay using hematopoietic stem cells. The ND50 of the antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of recombinant, mouse MIP1 alpha, which is present at five times its own EC50 (the concentration of recombinant, mouse MIP1 alpha producing a one-half maximal bioactivity without antibody).
Both MIP-1alpha and MIP-1beta are structurally and functionally related CC chemokines. They participate in host response to invading bacterial, viral, parasite and fungal pathogens by regulating the trafficking and activation state of selected subgroups of inflammatory cells (e.g. macrophages, lymphocytes and NK cells). While both MIP-1alpha and MIP-1beta exert similar effects on monocytes, their effect on lymphocytes differ; with MIP-1alpha selectively attracting CD8+ lymphocytes, and MIP-1beta selectively attracting CD4+ lymphocytes. Additionally, MIP-1alpha and MIP-1beta have also been shown to be potent chemoattractants for B cells, eosinophils and dendritic cells. Both human and murine MIP-1alpha and MIP-1beta are active on human and murine hematopoietic cells.
仅用于科研。不用于诊断过程。未经明确授权不得转售。